This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients
Leukemia Open Access 17 August 2023
-
Isocitrate dehydrogenase 1 mutation drives leukemogenesis by PDGFRA activation due to insulator disruption in acute myeloid leukemia (AML)
Leukemia Open Access 21 November 2022
-
Investigation of measurable residual disease in acute myeloid leukemia by DNA methylation patterns
Leukemia Open Access 15 June 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Juliusson G . Older patients with acute myeloid leukemia benefit from intensive chemotherapy: an update from the Swedish Acute Leukemia Registry. Clin Lymphoma Myeloma Leuk 2011; 11: S54–S59.
Hulegärdh E, Nilsson C, Lazarevic V, Garelius H, Antunovic P, Rangert Derolf Å et al. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry. Am J Hematol 2015; 90: 208–214.
Lazarevic V, Hörstedt A-S, Johansson B, Antunovic P, Billström R, Derolf A et al. Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population-based experience. Blood Cancer J 2014; 4: e188.
Tsai C-H, Hou H-A, Tang J-L, Liu C-Y, Lin C-C, Chou W-C et al. Genetic alterations and their clinical implications in older patients with acute myeloid leukemia. Leukemia 2016; 30: 1485–1492.
Büchner T, Berdel WE, Haferlach C, Haferlach T, Schnittger S, Müller-Tidow C et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 2009; 27: 61–69.
Metzeler KH, Herold T, Rothenberg-Thurley M, Amler S, Sauerland MC, Görlich D et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood 2016; 128: 686–698.
Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059–2074.
Metzeler KH, Becker H, Maharry K, Radmacher MD, Kohlschmidt J, Mrózek K et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood 2011; 118: 6920–6929.
Chou WC, Chou SC, Liu CY, Chen CY, Hou HA, Kuo YY et al. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood 2011; 118: 3803–3810.
Greif PA, Konstandin NP, Metzeler KH, Herold T, Pasalic Z, Ksienzyk B et al. RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes. Haematologica 2012; 97: 1909–1915.
Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik V, Paschka P, Roberts N et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 2016; 374: 2209–2221.
Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011; 478: 64–69.
Guryanova OA, Shank K, Spitzer B, Luciani L, Koche RP, Garrett-Bakelman FE et al. DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. Nat Med 2016; 22: 1488–1495.
Figueroa ME, Skrabanek L, Li Y, Jiemjit A, Fandy TE, Paietta E et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 2009; 114: 3448–3458.
Lin Q, Wagner W . Epigenetic aging signatures are coherently modified in cancer. PLoS Genet 2015; 11: e1005334.
Acknowledgements
We thank Liliana H Mochmann for the critical reading of the manuscript. This study was supported by Else Kröner-Fresenius-Stiftung (2013A153), the German Cancer Consortium (Deutsches Konsortium fur Translationale Krebsforschung DKTK, Heidelberg, Germany), the Deutsche Krebshilfe (Mildred Scheel Stiftungsprofessur, CDB) and the Deutsche Forschungsgemeinschaft (DFG EXC 1003, WEB). PS was supported by the Berlin School of Integrative Oncology (BSIO).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Silva, P., Neumann, M., Schroeder, M. et al. Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape. Leukemia 31, 1640–1644 (2017). https://doi.org/10.1038/leu.2017.109
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2017.109
This article is cited by
-
Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients
Leukemia (2023)
-
Isocitrate dehydrogenase 1 mutation drives leukemogenesis by PDGFRA activation due to insulator disruption in acute myeloid leukemia (AML)
Leukemia (2023)
-
Investigation of measurable residual disease in acute myeloid leukemia by DNA methylation patterns
Leukemia (2022)
-
How Genetics Can Drive Initial Therapy Choices for Older Patients with Acute Myeloid Leukemia
Current Treatment Options in Oncology (2022)
-
A deconvolution method and its application in analyzing the cellular fractions in acute myeloid leukemia samples
BMC Genomics (2020)